A leading PE firm was evaluating the possible acquisition opportunity of a generic drug manufacturing company. The target company had received several warning letters from the drug authorities, hence the evaluation was not normal. Our global FDA expert evaluated the warning letters, visited the plant locations and devised the strategies to mitigate the risk due to warning letters. The team managed to develop a probabilistic model based on his inputs.